Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular heterogeneity and immune infiltration drive clinical outcomes in upper tract urothelial carcinoma
    Journal Article

    Kim, K.; Alam, S. M.; Kuo, F.; Chen, Z.; Yip, W.; Katims, A. B.; Chu, C.; Lenis, A. T.; Hu, W.; Gokturk Ozcan, G.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma
    Journal Article

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Loss of KMT2C or KMT2D primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
    Journal Article

    Wang, N.; Pachai, M. R.; Li, D.; Lee, C. J.; Warda, S.; Khudoynazarova, M. N.; Cho, W. H.; Xie, G.; Shah, S. R.; Yao, L.; more...
    Nature Genetics (2025)

    Fulltext@MSK | Save
  • New treatment approaches in muscle-invasive bladder cancer
    Book Section

    Gupta, A.; Rosenberg, J. E.
    In Knowles, M. A.; Dyrskjøt, L. (Eds.) Biology of Bladder Cancer: From Molecular Insights to Clinical Strategies (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
    Meeting Abstract

    Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy for metastatic urothelial carcinoma: Final analysis from the phase II IMvigor210 trial
    Journal Article

    Rosenberg, J. E.; Galsky, M. D.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; van der Heijden, M. S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save